Merck licenses Dragonfly's immunotherapy for tumors

By The Science Advisory Board staff writers

November 23, 2021 -- Merck has licensed its second trispecific NK (TrinKet) immunotherapy candidate from Dragonfly Therapeutics for solid tumors.

In November 2020, Merck licensed its first TrinKet immunotherapy candidate from Dragonfly. Initially, Merck and Dragonfly's collaboration focused on solid tumor targets. Last year, their collaboration expanded to a multitarget agreement to develop and commercialize additional NK cell engager immunotherapies in oncology, infectious disease, and immune disorders.

Under the expanded agreement, Merck has exercised its option to license exclusive worldwide intellectual property rights on its second immunotherapy candidate developed using the TrinKet platform. Dragonfly has received an undisclosed payment associated with this milestone.

Merck, BioMed X extend collaboration in oncology, autoimmunity
Merck has extended its collaboration with German company BioMed X and will start six additional research projects at the BioMed X Institute. The projects...
Merck, Ridgeback to advance outpatient COVID-19 therapy to phase III trial
Merck and Ridgeback Biotherapeutics have announced they will move forward with a phase III trial of EIDD-2801/MK-4482 (molnupiravir), an oral antiviral...
Merck, Ridgeback anti-COVID-19 agent shows promise in clinical trials
Merck and Ridgeback Biotherapeutics have released results from a phase IIA clinical trial of the investigational oral antiviral agent EIDD-2801/MK-4482...
Bristol Myers licenses immunotherapy from Dragonfly
Bristol Myers Squibb has paid $12 million to Dragonfly Therapeutics to license a fourth immunotherapy drug candidate from Dragonfly's TrinKet portfolio.
Dragonfly, Bristol Myers Squibb to develop immunotherapies
Dragonfly Therapeutics has entered into a research collaboration with Bristol Myers Squibb to discover and develop novel immunotherapies for multiple...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter